--- title: "Legacy Capital Group California Inc. Buys New Position in AstraZeneca PLC $AZN" type: "News" locale: "en" url: "https://longbridge.com/en/news/278263981.md" description: "Legacy Capital Group California Inc. acquired a new position in AstraZeneca PLC, purchasing 5,287 shares valued at approximately $406,000 during Q3. Other institutional investors also adjusted their stakes, with Primecap Management Co. increasing its position by 1.3% and Franklin Resources Inc. by 0.9%. AstraZeneca's stock opened at $194.44, with a market cap of $301.56 billion and a PE ratio of 64.60. The company recently announced a dividend of $1.595, set to be paid on March 23rd, with a yield of 156.0%." datetime: "2026-03-08T11:41:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278263981.md) - [en](https://longbridge.com/en/news/278263981.md) - [zh-HK](https://longbridge.com/zh-HK/news/278263981.md) --- # Legacy Capital Group California Inc. Buys New Position in AstraZeneca PLC $AZN Legacy Capital Group California Inc. purchased a new position in AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 5,287 shares of the company's stock, valued at approximately $406,000. - As Investors Flee U.S. Equities, This Global ETF Is Outperforming Other large investors also recently made changes to their positions in the company. Primecap Management Co. CA grew its position in AstraZeneca by 1.3% in the second quarter. Primecap Management Co. CA now owns 41,200,091 shares of the company's stock worth $2,879,062,000 after buying an additional 538,606 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of AstraZeneca by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 21,298,394 shares of the company's stock valued at $1,488,332,000 after acquiring an additional 196,401 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of AstraZeneca by 2.3% in the 3rd quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company's stock worth $1,623,604,000 after acquiring an additional 466,745 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of AstraZeneca by 9.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company's stock valued at $521,517,000 after acquiring an additional 582,183 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in AstraZeneca by 2.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,046,992 shares of the company's stock valued at $351,734,000 after purchasing an additional 104,625 shares during the period. Institutional investors own 20.35% of the company's stock. ## AstraZeneca Price Performance Shares of AZN opened at $194.44 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. AstraZeneca PLC has a twelve month low of $122.48 and a twelve month high of $212.71. The firm's 50 day moving average price is $146.71 and its 200 day moving average price is $106.43. The firm has a market cap of $301.56 billion, a PE ratio of 64.60, a PEG ratio of 1.59 and a beta of 0.32. ## AstraZeneca Dividend Announcement - A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH The business also recently announced a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be issued a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date is Friday, February 20th. AstraZeneca's payout ratio is 66.26%. ## Analysts Set New Price Targets AZN has been the subject of several recent analyst reports. Barclays reaffirmed an "overweight" rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Morgan Stanley restated an "overweight" rating and set a $103.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 3rd. TD Cowen reaffirmed a "buy" rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Weiss Ratings reiterated a "buy (b)" rating on shares of AstraZeneca in a report on Wednesday, January 21st. Finally, Guggenheim reissued a "buy" rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $95.75. - Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All **Check Out Our Latest Research Report on AstraZeneca** ## AstraZeneca Company Profile (Free Report) AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca's operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide. The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases. ## Further Reading - Five stocks we like better than AstraZeneca - “I just bought 10,000 shares of a $5 stock…” - Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why - How JPMorgan's $8,000 Gold Call Will Leave Most Retirement Accounts Behind - Silver Is the New Oil—And the World’s Running Dry - Nvidia CEO Issues Bold Tesla Call **Want to see what other hedge funds are holding AZN?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report). _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in AstraZeneca Right Now? Before you consider AstraZeneca, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list. While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) ## Related News & Research - [Key facts: Citi expects AstraZeneca to reaffirm FY guidance; boosts Q1 spend](https://longbridge.com/en/news/282398247.md) - [AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study](https://longbridge.com/en/news/282072509.md) - [Cloudflare, Inc. Launches Cloudflare Mesh](https://longbridge.com/en/news/282733341.md) - [BUZZ-IDEAYA rises after lung cancer drug combo testing deal with AstraZeneca](https://longbridge.com/en/news/282173989.md) - [AstraZeneca says Efzimfotase alfa PH3 program show positive results](https://longbridge.com/en/news/281138062.md)